ARTIFICIAL INTELLIGENCE BUILT TO IDENTIFY & PREDICT DEVELOPMENT OF CANCER SYMPTOMS CLUSTERS 

Prof.Dr.Dram,profdrram@gmail.com,Gastro Intestinal,Liver Hiv,Hepatitis and sex diseases expert 7838059592,943414355    www.blogspot.com/drnakipuria     www.bhartiyanews24x7.com    www.bhartiyanews24x7.net      www.Bharatiyanews24x7.com

Cancer patients who undergo chemotherapy could soon benefit from a new AI (artificial intelligence) that is able to identify and predict the development of different combinations of symptoms – helping to alleviate much of the distress caused by their occurrence and severity.

In a first study of its kind, published by Nature Scientific Reports, researchers from the University of Surrey (UK) and the University of California (US) detail how they used Network Analysis (NA) to examine the structure and relationships between 38 common symptoms reported by over 1300 cancer patients receiving chemotherapy.

Some of the most common symptoms reported by patients were nausea, difficulty concentrating, fatigue, drowsiness, dry mouth, hot flushes, numbness, and nervousness.

The team then grouped these symptoms into three key networks – occurrence, severity and distress. The NA allowed the team to identify nausea as central – impacting symptoms across all three different key networks.

According to Cancer Research UK, 360,000 people are diagnosed with cancer every year – with breast, prostate, lung and bowel cancers counting for over half of new cases in the UK. Around 28 per cent of patients diagnosed with cancer in England have curative or palliative chemotherapy as part of their primary cancer treatment.

Payam Barnaghi, Professor of Machine Intelligence at the Centre for Vision, Speech and Signal Processing (CVSSP) at the University of Surrey, said: “This is the first use of Network Analysis as a method of examining the relationships between common symptoms suffered by a large group of cancer patients undergoing chemotherapy. The detailed and intricate analysis this method provides could become crucial in planning the treatment of future patients – helping to better manage their symptoms across their healthcare journey.”

Nikolaos Papachristou, co-author of the study and research student from CVSSP, said: “I am proud of our continued work to support cancer patients during their treatment and improving their quality of life with the help of machine learning.”

Professor Adrian Hilton, Director of CVSSP, said: “This is another heartening development from Professor Barnaghi and his group. This world-first study of how NA methods can help identify and analyse the symptoms of cancer patients supports the real benefits machine learning brings to society and the future of the healthcare industry.”

Professor Christine Miaskowski from the University of California said: “This fresh approach will allow us to develop and test novel and more targeted interventions to decrease symptom burden in cancer patients undergoing chemotherapy.”